title: Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
abstract: A large body of data suggest that brain cholecystokinin (CCK) systems are involved in the regulation of anxiety, and numerous studies have demonstrated that CCK-4, a CCKB agonist, reliably induces panic attacks in patients with panic disorder. Recently, pentagastrin, a commercially available CCKB agonist, has been reported to have similar anxiogenic properties. To further explore the utility of pentagastrin as a challenge agent and to determine whether its effects are dose-related, a dose-response study was conducted in ten healthy volunteers. Pentagastrin (0.2 microgram/kg, 0.6 microgram/kg and 1.0 microgram/kg) and inactive placebo were infused over one minute on four separate challenge days in a double-blind fashion. Subjects received pentagastrin while participating in a structured social interaction task. Repeated measures of anxiety, blood pressure, pulse, ACTH, and cortisol were taken at baseline and postinfusion. Pentagastrin administration led to increases in anxiety, pulse, ACTH, cortisol and physical symptoms of panic, in a dose-related manner. Participation in the social interaction task led to increases in measures of anxiety as well as increases in pulse and blood pressure. Few differences were found between the 0.2 microgram/kg dose of pentagastrin and placebo, or between the 0.6 microgram/kg and the 1.0 microgram/kg doses of pentagastrin. These findings support the notion that CCK systems are involved in the regulation of anxiety, and suggest that the 0.6 microgram/kg dose may be optimal for increasing symptoms of anxiety while minimizing unpleasant side effects. The powerful anxiogenic effects of the social interaction task underscore the importance of contextual variables in challenge studies.
authors.affiliation: Section on Anxiety and Affective Disorders, NIMH, NIH, Bethesda, Maryland 20892, USA.
authors.forename: U D
authors.initials: UD
authors.lastname: McCann
authors.forename: S O
authors.initials: SO
authors.lastname: Slate
authors.forename: M
authors.initials: M
authors.lastname: Geraci
authors.forename: T W
authors.initials: TW
authors.lastname: Uhde
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D001007:Anxiety / Q000139:chemically induced* / Q000503:physiopathology; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D010200:Panic / Q000187:drug effects* / Q000502:physiology; D010418:Pentagastrin / Q000494:pharmacology*; D010555:Personality Inventory; D010698:Phobic Disorders / Q000503:physiopathology; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000187:drug effects / Q000502:physiology; D012381:Role Playing; D012931:Social Environment; D013758:Tetragastrin / Q000494:pharmacology
chemical_list: D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D013758:Tetragastrin; D000324:Adrenocorticotropic Hormone; D010418:Pentagastrin; D006854:Hydrocortisone